RAPT Therapeutics has been granted a patent for pyrazole pyrimidine compounds that target hematopoietic progenitor kinase 1. The compounds can be used for therapeutic purposes. GlobalData’s report on RAPT Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights RAPT Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on RAPT Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. RAPT Therapeutics's grant share as of April 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11918582B2) discloses a compound of formula (I) and its pharmaceutically acceptable salts for the treatment of diseases associated with hematopoietic progenitor kinase 1 (HPK1) activity. The compound, not including a specific chemical structure, is designed to target HPK1, a key player in various diseases, particularly cancer. The patent also covers a pharmaceutical composition containing the compound and a method for treating diseases like cancer by administering the compound or its salt to patients in need.

Furthermore, the patent outlines a method for treating cancer using the disclosed compound in combination with anti-cancer drugs, specifically immune checkpoint inhibitors targeting various proteins like CTLA-4, PD-1, PD-L1, and others. The method covers a wide range of cancers, including brain, skin, breast, prostate, and blood cancers, among others. Additionally, the patent extends the application of the compound to treat diseases beyond cancer, such as viral and bacterial infections, age-related immune decline, and infertility. The compound's chemical structure is not explicitly provided in the claims, emphasizing its broad applicability in treating a diverse range of diseases beyond cancer.

To know more about GlobalData’s detailed insights on RAPT Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies